Advanced glycation end products: a Nephrologist's perspective.
about
Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidneyCurrent perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary managementLow levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or realityThe role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease.Rapid Myoglobin Aggregation through Glucosamine-Induced α-Dicarbonyl Formation.Serum arylhydrocarbon receptor transactivating activity is elevated in type 2 diabetic patients with diabetic nephropathyQuantification of N2-carboxymethyl-2'-deoxyguanosine in calf thymus DNA and cultured human kidney epithelial cells by capillary high-performance liquid chromatography-tandem mass spectrometry coupled with stable isotope dilution methodMethylglyoxal and Advanced Glycation End products: Insight of the regulatory machinery affecting the myogenic program and of its modulation by natural compounds.Alterations in T2 relaxation magnetic resonance imaging of the ovine intervertebral disc due to nonenzymatic glycation.Survival in dialysis patients is not different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid conditionTherapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.3-Deoxyglucosone: a potential glycating agent accountable for structural alteration in H3 histone protein through generation of different AGEs.Emerging drugs for renal failure.Skin Autofluorescence Is Associated with Endothelial Dysfunction in Uremic Subjects on Hemodialysis.Chronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal DiseaseLow-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more?Neo-Epitopes Generated on Hydroxyl Radical Modified GlycatedIgG Have Role in Immunopathology of Diabetes Type 2Skin Autofluorescence and Subclinical Atherosclerosis in Mild to Moderate Chronic Kidney Disease: A Case-Control Study.Activation of endothelial NAD(P)H oxidase accelerates early glomerular injury in diabetic miceAdvanced glycation end-products reduce podocyte adhesion by activating the renin-angiotensin system and increasing integrin-linked kinase.Dietary glycotoxins and infant formulas.Advanced glycation end products, oxidative stress and diabetic nephropathy.Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy.Peritoneal changes in patients on long-term peritoneal dialysis.Protein folding, misfolding, aggregation and their implications in human diseases: discovering therapeutic ways to amyloid-associated diseases.Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.Advanced glycation End-products (AGEs): an emerging concern for processed food industries.AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.Neuropathy induced by exogenously administered advanced glycation end-products in rats.Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors.Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial.Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Non-invasive Technique - Skin Autofluorescence.Methylglyoxal induces oxidative stress and mitochondrial dysfunction in osteoblastic MC3T3-E1 cells.The early glycation products of the Maillard reaction: mass spectrometric characterization of novel imidazolidinones derived from an opioid pentapeptide and glucose.Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells.Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients.Advanced glycation end products in hemodialyzed patients with diabetes mellitus correlate with leptin and leptin/body fat ratio.Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice.
P2860
Q24292412-B537B4BF-9C7C-4BF1-A7F3-C242D15F268AQ26781156-DCFA5C81-4D2D-415E-B2A6-1EBE8898AAE7Q26859793-A27B8DC6-D1EE-4A92-8976-36115A087B56Q30340930-1ED2BDF4-48A2-43E7-A2DC-58B544A32208Q30379535-D1580382-E35A-4EDC-BD37-139BD2FD5056Q33628239-CEE8133E-36D7-4184-A773-8EA7C9D3312CQ33638705-9D8C51FE-CEB4-4FE8-8330-682537CC497AQ33918540-A2FD49A5-3966-4AB8-9509-7DE4D4CF7221Q33998584-84C0210F-020C-49B5-99CC-F47A73309E62Q34105962-60F3CE93-5C58-4A92-8E61-731DFD16318BQ34481838-159274F0-D2EF-403B-979E-6F28254E4B6BQ35562725-F5B93C2E-9DBC-451B-9AC7-A9A262A71E9DQ35602657-ABB157AF-8F77-4E0A-8906-DDAD38E1252FQ35904085-BD3D99F3-0127-46E4-BBF2-B41F9BB5650BQ36036008-B6A0114F-C490-43BA-9D64-9EA79C1C90D7Q36203996-1CC2B998-6626-4587-9632-E0D7E9FDB798Q36238600-A60B313F-201C-4149-8815-23878F9F4A61Q36264876-4A72076C-3B27-4D7F-A6E9-630A39D8215DQ36921163-0798DAC5-8D02-4ABA-A9E0-D7AAB70945EBQ37313263-DD64D2DE-7245-4BB4-BC37-B60788B1A63BQ37591929-56AAB97E-F452-4F23-B5CA-9BF34A5D8EBCQ37780646-DB6C4755-D4FD-4266-96B4-D450E64E6F76Q38006722-3DF25CA6-5692-4940-8502-5389CE9FF3CAQ38083574-2B0BB1E1-000D-45DE-B44A-8D6A94642EACQ38106610-571CA6DE-A48F-496D-9D11-6F39FB57276EQ38196753-0F7231C0-67F4-4539-B6BE-A845D8007E7AQ38243632-5302992D-0AD4-48A6-B3D0-B790F14A2697Q38523267-53C01E21-F1B0-4314-81F4-B6A4B61352B8Q38647079-C9928417-F05A-46E0-B254-7364CB675BC6Q39313922-AD486F4F-1DAC-4BAA-9F17-0711B8026EA1Q39603238-80942960-A47D-47F2-8DC8-F5D48D0C243EQ40394729-FBA82CEF-37E5-441E-955B-B45CB423D60EQ41836455-D5E35FCB-9FA2-4477-BEF2-F6BF5213F483Q42120056-9441E15D-17AD-4552-8F10-241E422D46CBQ42811134-C10C9130-64A1-4153-9FA6-829CC50FF7FDQ43635729-A33EAE7B-8DFC-40E5-883F-E9BE9436AD17Q43931414-792AE3EE-25B0-46CC-AFC9-180DA257F011Q44414030-33D130C5-7A2B-41CD-BC05-7329E9F2B090Q44435947-FD50D8A7-95EC-4CFA-A97D-E4017CB30875Q45979790-BE0A67B6-7798-4F50-AFFE-5EB5AB9ADF1E
P2860
Advanced glycation end products: a Nephrologist's perspective.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Advanced glycation end products: a Nephrologist's perspective.
@ast
Advanced glycation end products: a Nephrologist's perspective.
@en
type
label
Advanced glycation end products: a Nephrologist's perspective.
@ast
Advanced glycation end products: a Nephrologist's perspective.
@en
prefLabel
Advanced glycation end products: a Nephrologist's perspective.
@ast
Advanced glycation end products: a Nephrologist's perspective.
@en
P2093
P1476
Advanced glycation end products: a Nephrologist's perspective.
@en
P2093
P304
P356
10.1016/S0272-6386(00)70189-2
P577
2000-03-01T00:00:00Z